Suppr超能文献

在全科医学中使用阿片类药物治疗慢性非癌症疼痛:当前证据概述。

Using opioids in general practice for chronic non-cancer pain: an overview of current evidence.

机构信息

Flinders University, Adelaide, SA

UTS Sydney, Sydney, NSW.

出版信息

Med J Aust. 2016 May 2;204(8):305-9. doi: 10.5694/mja16.00066.

Abstract

Chronic non-cancer pain (lasting more than 3 months) is highly prevalent in Australia (17% of males and 20% of females) and its optimal management is crucial to the health and wellbeing of the community. For 5% of the population, such pain interferes markedly with daily function. Part of the treatment for acute non-cancer pain for many people will include opioid analgesics at least for days to weeks. However, as pain becomes chronic, evidence to support ongoing prescription of opioids is lacking. There is increasing pressure to ensure that prescribing opioid analgesics is minimised to reduce not only the risk of dependence and illicit diversion but also the potential harms associated with tolerance, side effects and complications. Frameworks for considering opioid prescribing include assessing suitability of the patient for opioids; initiating a trial of therapy; and monitoring long term use. There is limited evidence of the long term efficacy of opioids for chronic non-cancer pain, and documented clinical consequences beyond addiction include acceleration of loss of bone mineral density, hypogonadism and an association with increased risk of acute myocardial infarction. Careful clinical selection of patients can help optimise the evidence-based use of opioids for chronic non-cancer pain: only treat pain that has been as well defined as possible when non-opioid therapies have not been effective; consider referral to specialist services for assessment if doses are above 100 mg oral morphine equivalent per 24 hours or the duration of therapy is longer than 4 weeks; limit prescribing to only one practitioner; seek an agreement with the patient for the initiation and potential withdrawal of opioids if the therapeutic trial is not effective.

摘要

慢性非癌性疼痛(持续超过 3 个月)在澳大利亚非常普遍(男性为 17%,女性为 20%),其最佳管理对社区的健康和福祉至关重要。对于 5%的人口来说,这种疼痛会严重干扰日常功能。对于许多急性非癌性疼痛患者,部分治疗将包括至少数天至数周的阿片类镇痛药。然而,随着疼痛变为慢性,缺乏持续开处阿片类药物的证据。为了减少依赖和非法转用的风险,以及耐受、副作用和并发症相关的潜在危害,越来越需要确保尽量减少阿片类药物的处方。考虑开处阿片类药物的框架包括评估患者是否适合使用阿片类药物;开始试用治疗;以及监测长期使用情况。对于慢性非癌性疼痛,阿片类药物的长期疗效证据有限,除了成瘾之外,还有记录在案的临床后果包括骨矿物质密度加速丧失、性腺功能减退以及与急性心肌梗死风险增加有关。对患者进行仔细的临床选择有助于优化阿片类药物治疗慢性非癌性疼痛的循证使用:仅在非阿片类药物治疗无效时治疗已经尽可能明确界定的疼痛;如果剂量超过 100 毫克口服吗啡当量/24 小时或治疗持续时间超过 4 周,则考虑转介给专科评估;限制仅由一名医生开处方;如果治疗试验无效,与患者达成开始和潜在停用阿片类药物的协议。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验